CD47在乳腺癌及癌旁组织中的表达及其意义

Expression and significance of CD47 in breast cancer and pericancerous tissues

目的研究乳腺癌组织及癌旁组织中CD47的表达及其与临床预后及病理特征的相关性。方法分析TCGA数据库中乳腺癌CD47表达情况及其与临床预后的相关性;选取金陵医院2011-2015年期间185例乳腺癌患者,应用免疫组化方法评价乳腺癌组织及乳腺癌旁组织中CD47的表达情况,分析其与患者临床病理特征及预后的相关性。结果TCGA数据库中CD47基因扩增及mRNA表达上调者比例为2.6%(22/825),CD47基因表达上调组中位总生存期低于正常组(55.6个月vs 113.7个月,P=0. 0256)。乳腺癌组织CD47阳性表达率为56.21%(104/185),癌旁组织中阳性表达率为12.97%(24/185),癌与癌旁组织表达差异存在统计学意义(P<0. 01)。CD47表达与年龄相关(P<0. 05),与雌激素受体(ER)状态、孕激素受体(PR)状态、人类表皮生长因子受体2(Her2)状态、有无淋巴结转移、临床分期及患者预后未见相关。结论乳腺癌组织中CD47的表达显著高于癌旁组织,且与患者年龄相关,但癌组织中CD47表达与患者临床病理特征未见相关。

Objective To study the expression of CD47 in breast cancer tissues and pericancerous tissues and its correlation with clinical prognosis and pathological characteristics. Methods The expression of CD47 and its correlation with clinical prognosis were analyzed in The Cancer Genome Atlas （TCGA） database. From 2011 to 2015, 185 cases of breast cancer were selected in Jinling Hospital. The expression of CD47 in breast cancer tissues and pericancerous tissues was evaluated by immunohistochemistry （IHC ） assay. And its correlation with the clinicopathological features and prognosisof the patients was analyzed. Results The proportion of CD47 gene amplification and its mRNA expression increase was 2.6% （22/825） in TCGA database. The median OS of breast cancer group was lower than that in normal group （55.6 vs 113.7 months, P =0.0256）. CD47 expression was detected in 56.21% （104/185） breast cancer tissues and 12.97% （24/185） pericancerous tissues （ P 〈0.01）. The expression of CD47 was related to age（ P 〈0.05）, but there was no significant correlation with the expression of ER, PR, and Her2, lymph node metastasis, clinical stage and prognosis. Conclusion The expression of CD47 was significantly higher in breast cancer tissues than that in pericancerous tissues, which is related to age. However,there was no significant correlation between the expression of CD47 and the clinicopathological characteristics of the breast cancer patients.